Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Atrial conduction disorder is a form of heart disease in which the conduction of the cardiac atrium is disrupted.
Features include sometimes findings: Congestive heart failure; and rarely findings: Cardiac arrest. 13 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Heart and blood vessels | 11 | Paroxysmal supraventricular tachycardia, Cardiac arrest, Atrial arrhythmia |
TNNI3K function has not been fully characterized.
Atrial conduction disease is associated with mutations in the TNNI3K gene on chromosome 1.
Genetic testing for TNNI3K is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for atrial conduction disease has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for atrial conduction disease.
240 publications have been identified in PubMed for atrial conduction disease. Research spans Basic Science / Preclinical (32%), Epidemiology / Natural History (23%), and Review / Meta-Analysis (18%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 76 | 32% |
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 3:40 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
1 |
Left anterior fascicular block |
Muscles | 1 | Left anterior fascicular block |
56 |
23% |
Research summaries | 43 | 18% |
Clinical study results | 18 | 8% |
Patient case studies | 17 | 7% |
New treatment approaches | 14 | 6% |
Testing and diagnosis research | 13 | 5% |
Other research | 3 | 1% |
Abdul Jabbar AB (2026). [PMID: 41493497](https://pubmed.ncbi.nlm.nih.gov/41493497/). *Curr Atheroscler Rep*. [Review / Meta-Analysis]
Floyd BJ (2026). [PMID: 41949880](https://pubmed.ncbi.nlm.nih.gov/41949880/). *JAMA Cardiol*. [Gene Therapy / Novel Therapeutics]
Sellal JM (2026). [PMID: 40679844](https://pubmed.ncbi.nlm.nih.gov/40679844/). *Eur Heart J*. [Basic Science / Preclinical]
Magen E (2026). [PMID: 41520806](https://pubmed.ncbi.nlm.nih.gov/41520806/). *Am J Med*. [Epidemiology / Natural History]
Angelotti A (2026). [PMID: 41453508](https://pubmed.ncbi.nlm.nih.gov/41453508/). *J Mol Cell Cardiol*. [Epidemiology / Natural History]
Micheu MM (2026). [PMID: 41977344](https://pubmed.ncbi.nlm.nih.gov/41977344/). *Int J Mol Sci*. [Review / Meta-Analysis]
Wang Z (2026). [PMID: 41679653](https://pubmed.ncbi.nlm.nih.gov/41679653/). *Int J Cardiol*. [Gene Therapy / Novel Therapeutics]
Liu Y (2026). [PMID: 41861523](https://pubmed.ncbi.nlm.nih.gov/41861523/). *Biomed Pharmacother*. [Review / Meta-Analysis]
Lassen MCH (2026). [PMID: 41779388](https://pubmed.ncbi.nlm.nih.gov/41779388/). *JAMA Cardiol*. [Basic Science / Preclinical]
Muharram M (2026). [PMID: 41582218](https://pubmed.ncbi.nlm.nih.gov/41582218/). *J Med Case Rep*. [Review / Meta-Analysis]